Document Detail


Added diagnostic value of CSF biomarkers in differential dementia diagnosis.
MedLine Citation:
PMID:  19150153     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This study aimed to investigate whether cerebrospinal fluid (CSF) biomarkers could have helped the clinician in differential dementia diagnosis in case of clinically ambiguous diagnoses, as compared to autopsy-confirmed dementia diagnosis as gold standard. Twenty-two patients of our autopsy-confirmed dementia population totalling 157 patients had an ambiguous clinical diagnosis at CSF sampling and were included in statistical analysis. CSF levels of β-amyloid peptide (Aβ(1-42)), total tau protein (T-tau) and tau phosphorylated at threonine 181 (P-tau(181P)) were determined. A biomarker-based model was applied to discriminate between AD and NON-AD dementias. AD and NON-AD patients showed no significant differences in Aβ(1-42) and T-tau concentrations, whereas P-tau(181P) concentrations were significantly higher in AD compared to NON-AD patients. The biomarker-based diagnostic model correctly classified 18 of 22 (82%) patients with clinically ambiguous diagnoses. Using a biomarker-based model in patients with clinically ambiguous diagnoses, a correct diagnosis would have been established in the majority of autopsy-confirmed AD and NON-AD cases, indicating that biomarkers have an added diagnostic value in cases with ambiguous clinical diagnoses.
Authors:
Nathalie Le Bastard; Jean-Jacques Martin; Eugeen Vanmechelen; Hugo Vanderstichele; Peter Paul De Deyn; Sebastiaan Engelborghs
Related Documents :
6497353 - Brain electrical activity in patients with presenile and senile dementia of the alzheim...
1456073 - Folate, vitamin b12 and cognitive impairment in patients with alzheimer's disease.
22387173 - Quantitative evaluation of white matter tract dti parameter changes in gliomas using no...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-01-15
Journal Detail:
Title:  Neurobiology of aging     Volume:  31     ISSN:  1558-1497     ISO Abbreviation:  Neurobiol. Aging     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-09-27     Completed Date:  2011-01-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8100437     Medline TA:  Neurobiol Aging     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1867-76     Citation Subset:  IM    
Copyright Information:
Copyright © 2008 Elsevier Inc. All rights reserved.
Affiliation:
Reference Center for Biological Markers of Memory Disorders, Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Alzheimer Disease / cerebrospinal fluid,  diagnosis*
Amyloid beta-Peptides / cerebrospinal fluid*,  diagnostic use
Biological Markers / cerebrospinal fluid
Case-Control Studies
Dementia / cerebrospinal fluid,  diagnosis*
Diagnosis, Differential
Female
Humans
Male
Models, Biological
Peptide Fragments / cerebrospinal fluid*,  diagnostic use
Sensitivity and Specificity
tau Proteins / cerebrospinal fluid*,  diagnostic use
Chemical
Reg. No./Substance:
0/Amyloid beta-Peptides; 0/Biological Markers; 0/Peptide Fragments; 0/amyloid beta-protein (1-42); 0/tau Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Novel mutations in GCK and HNF1A genes in Italian families with MODY phenotype.
Next Document:  SAR study of clubbed [1,2,4]-triazolyl with fluorobenzimidazoles as antimicrobial and antituberculos...